ReviewJournal of analytical toxicology2026
Tramadol in drug-facilitated sexual assault: global case prevalence, pharmacology, and drug interactions.
Review in Journal of analytical toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-facilitated sexual assault (DFSA) refers to sexual acts where the victim is incapacitated by the effects of psychotropic substances, causing impaired ability to prevent an attack and/or provide informed consent. To date, the level of understanding of the prevalence of the specific drugs involved in DFSA has been limited. This review examines global toxicological case data to assess the prevalence of tramadol, a widely prescribed opioid analgesic, in the context of DFSA. Tramadol was confirmed in reports across Africa, Oceania, Europe, the Middle East, and North America, with detection rates ranging from 1% to 33%. In these cases, 17 voluntary and involuntary drug combinations were identified including alcohol, opioids, benzodiazepines, Z-drugs, cannabinoids, and stimulants. These substances pose significant risk for both pharmacodynamic and pharmacokinetic interaction with tramadol, potentially altering plasma metabolite levels, clearance times and also central nervous system depression, facilitating DFSA and influencing forensic detection and interpretation of tramadol and its metabolites. Overall, this review underscores the significance of tramadol in DFSA casework and highlights the importance of drug-drug interactions in order to improve forensic analysis in DFSA casework and aid in legal action leading to victim support and closure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.